Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2022 [J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[2]
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022 [J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[3]
Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer [J]. J Hematol Oncol, 2019, 12(1): 47.
[4]
Wang S, Zimmermann S, Parikh K, et al. Current diagnosis and management of Small-Cell Lung Cancer [J]. Mayo Clin Proc, 2019, 94(8): 1599-1622.
[5]
Lázaro S, Pérez-crespo M, Enguita A B, et al. Correction: ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation [J]. Oncotarget, 2017, 8(30): 50323.
[6]
Rudin C M, Poirier J T, Byers L A, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data [J]. Nat Rev Cancer, 2019, 19(5): 289-297.
[7]
Liu Q, Zhang J, Guo C, et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies [J]. Cell, 2024, 187(1): 184-203.
[8]
Kazemi M, Ladbury C, Liu J, et al. Thoracic radiation in limited stage small cell lung cancer: trends in radiation fractionation [J]. Clin Lung Cancer, 2023, 24(4): 322-328.
[9]
Faivre-finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial [J]. Lancet Oncol, 2017, 18(8): 1116-1125.
[10]
Watkins J M, Russo J K, Andresen N, et al. Long-term outcome comparison for standard fractionation (>59 Gy) versus hyperfractionated (>45 Gy) radiotherapy plus concurrent chemotherapy for limited-stage small-cell lung cancer [J]. Rep Pract Oncol Radiother, 2020, 25(4): 489-493.
[11]
Bogart J, Wang X, Masters G, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538 [J]. J Clin Oncol, 2023, 41(13): 2394-2402.
[12]
Xie L, Fan X, Qian B. Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer [J]. Lancet Oncol, 2021, 22(6): e221.
[13]
Fried D B, Morris D E, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer [J]. J Clin Oncol, 2004, 22(23): 4837-4845.
[14]
Paz-ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J]. Lancet, 2019, 394(10212): 1929-1939.
[15]
Horn L, Mansfield A S, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer [J]. N Engl J Med, 2018, 379(23): 2220-2229.
[16]
Bonanno L, Pavan A, Dieci M V, et al. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes [J]. Eur J Cancer, 2018, 101: 191-200.
[17]
Welsh J W, Heymach J V, Guo C, et al. Phase 1/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC [J]. J Thorac Oncol, 2020, 15(12): 1919-1927.
[18]
Peters S, Pujol J L, Dafni U, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial [J]. Ann Oncol, 2022, 33(1): 67-79.
[19]
Cheng Y, Spigel D R, Cho B C, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer [J]. N Engl J Med, 2024, 391(14): 1313-27.
Wang X, Zeng X, Li D, et al. PARP inhibitors in small cell lung cancer: the underlying mechanisms and clinical implications [J]. Biomedicine & Pharmacotherapy, 2022, 153: 113458.
[22]
Shen W, Lyu Q, Yi R, et al. HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy [J]. J Adv Res, 2024,12(66):165-186.
[23]
Woll P, Gaunt P, Danson S, et al. Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): a randomised, double-blind, placebo-controlled phase II trial [J]. Lung Cancer, 2022, 171: 26-33.
[24]
Li Z, Zhang B, Yang F, et al. Pathological complete response to radical surgery after receiving durvalumab plus neoadjuvant chemotherapy for 1 limited-stage small cell lung cancer patient: a case report [J]. Transl Cancer Res, 2022, 11(4): 973-979.
[25]
Lu M, Zhang R, Qi L S, et al. Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer [J]. Thoracic Cancer, 2022, 13(22): 3208-3216.
[26]
Duan H, Shi L, Shao C, et al. A multicenter, single-arm, open study of neoadjuvant or conversion atezolizumab in combination with chemotherapy in resectable small cell lung cancer (Cohort Study) [J]. Int J Surg, 2023, 109(9): 2641-2649.
[27]
Sun F, Hu J, Sun L, et al. 1991P Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: a phase II trial [J]. Annals of Oncology, 2023, 34: S1062.
[28]
Peng H, Hao J, Dong B, et al. Prophylactic cranial irradiation in patients with resected small-cell lung cancer: a systematic review and meta-analysis [J]. Thorac Cancer, 2024, 15(32): 2309-2318.
[29]
Xu J, Yang H, Fu X, et al. Prophylactic cranial irradiation for patients with surgically resected small cell lung cancer [J]. J Thorac Oncol, 2017, 12(2): 347-353.
[30]
Chen Y, Wang Y, Ren F, et al. Prophylactic cranial irradiation (PCI) versus active surveillance in patients with limited-stage small cell lung cancer: a retrospective, multicentre study [J]. Respir Res, 2022, 23(1): 274.
[31]
Liu J, Shen B, Yang Y, et al. Survival benefit of prophylactic cranial irradiation in limited-stage small-cell lung cancer in modern magnetic resonance imaging staging: a systematic review and meta-analysis [J]. Acta Oncol, 2023, 62(3): 305-314.
[32]
Yan M, Toh T S, Lindsay P E, et al. Limited-stage small cell lung cancer: outcomes associated with prophylactic cranial irradiation over a 20-year period at the Princess Margaret Cancer Centre [J]. Clin Transl Radiat Oncol, 2021, 30: 43-49.
[33]
Wolfson A H, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2011, 81(1): 77-84.
[34]
Cho Y, Lee J, Lee I J, et al. Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients [J]. Sci Rep, 2021, 11(1): 7435.
[35]
VallièreS E, Shepherd F A, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer [J]. J Thorac Oncol, 2009, 4(9): 1049-1059.
[36]
Fernandez-cuesta L, Perdomo S, Avogbe P H, et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer[J]. EBioMedicine, 2016, 10: 117-123.
[37]
Acheampong E, Abed A, Morici M, et al. Tumour PD-L1 expression in small-cell lung cancer: a systematic review and meta-analysis [J]. Cells, 2020, 9(11):2393.
[38]
Liu C, Wang Z, Zeng Q, et al. PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma [J]. Genes Dis, 2023, 10(1): 48-50.
[39]
Baek J M, Cha H, Moon Y, et al. A systemic immune inflammation index and PD-L1 (SP142) expression as a potential combined biomarker of the clinical benefit of chemo-immunotherapy in extensive-stage small-cell lung cancer[J]. J Clin Med, 2024, 13(5):15-21.
[40]
Lim J U, Kang H S. A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer [J]. Ann Transl Med, 2021, 9(9): 809.
[41]
Gay C M, Stewart C A, Park E M, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities [J]. Cancer Cell, 2021, 39(3): 346-360.
2025, Vol. 36 
